Dilip Shanghvi is the Indian billionaire who started with just Rs 10,000 and two employees. He is the founder of Sun Pharmaceuticals, which has grown into one of the largest pharmaceutical companies in India and globally.

Shanghvi’s journey began in 1982 when he established Sun Pharmaceuticals with a small investment. Over the years, through strategic acquisitions and a focus on research and development, he expanded the company significantly. As of now, his net worth is estimated to be around Rs 2,74,000 crore, surpassing that of Cyrus Poonawalla, who is known for founding the Serum Institute of India, the world’s largest vaccine manufacturer.

Sun Pharmaceuticals has reported impressive annual revenues, reaching approximately $5.4 billion (around Rs 44,971 crore), showcasing the company’s robust growth and Shanghvi’s successful leadership. His story is often cited as an inspiring example of entrepreneurship in India, demonstrating how a modest beginning can lead to monumental success in the business world.

Under Shanghvi’s leadership, Sun Pharmaceuticals expanded rapidly, entering the US market in 1997 by acquiring Caraco Pharma. A significant milestone was reached in 2014 when Sun Pharma acquired Ranbaxy Laboratories for Rs 19,000 crore, making it India’s largest pharmaceutical company. In 2023, the company completed a $576 million acquisition of US-based Concert Pharmaceuticals, further solidifying its global presence. Shanghvi’s enterprise now generates nearly two-thirds of its reported $5.3 billion annual revenue from international markets, highlighting the company’s strong global footprint.